公开(公告)号：US20240016911A1

公开(公告)日：2024-01-18

申请号：US18455685

申请日：2023-08-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Ricarda HANNEN ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Franziska HOFFGAARD ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR

IPC: A61K35/17 ,  C07K14/725 ,  A61K45/06 ,  A61P37/04

CPC classification number: A61K35/17 ,  C07K14/7051 ,  A61K45/06 ,  A61P37/04

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240016909A1

公开(公告)日：2024-01-18

申请号：US18451883

申请日：2023-08-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Ricarda HANNEN ,  Christoph SCHRAEDER ,  Jens FRITSCHE ,  Franziska HOFFGAARD ,  Daniel Johannes KOWALEWSKI ,  Oliver SCHOOR

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/74

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K14/705 ,  C07K14/70539 ,  A61K39/00 ,  A61K2039/5158

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230338489A1

公开(公告)日：2023-10-26

申请号：US18323577

申请日：2023-05-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00 ,  G16B25/10

CPC classification number: A61K39/0011 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0638 ,  C07K14/71 ,  C07K14/7051 ,  C07K16/2863 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/57484 ,  C07K14/4748 ,  C07K16/30 ,  C07K7/06 ,  C12N5/0636 ,  C07K16/2869 ,  C07K14/721 ,  C12Y207/07031 ,  C12N9/1264 ,  C07K16/38 ,  C07K14/8135 ,  C07K14/47 ,  C12Y116/01 ,  C07K16/40 ,  C12N9/0091 ,  C07K14/705 ,  C07K16/28 ,  G16B25/00 ,  G16B25/10 ,  C07K2319/40 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230312679A1

公开(公告)日：2023-10-05

申请号：US18154091

申请日：2023-01-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  A61K51/10 ,  C12N15/115 ,  G01N33/569 ,  C12P21/02 ,  C07K14/47 ,  C12Q1/6881 ,  C07K14/705 ,  C12N5/0783 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K14/70539 ,  A61K39/0011 ,  A61K51/1027 ,  A61K51/1057 ,  C07K14/4748 ,  C07K14/70503 ,  C07K16/303 ,  C07K16/2833 ,  C12N5/0636 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/56977 ,  A61K2039/572 ,  A61K2039/5158 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/55 ,  C12N2310/16 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241115A1

公开(公告)日：2023-08-03

申请号：US18173177

申请日：2023-02-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241113A1

公开(公告)日：2023-08-03

申请号：US18170698

申请日：2023-02-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241108A1

公开(公告)日：2023-08-03

申请号：US18164407

申请日：2023-02-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230220045A1

公开(公告)日：2023-07-13

申请号：US18154098

申请日：2023-01-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K16/30 ,  C07K16/28 ,  C12P21/02 ,  A61K51/10 ,  A61K39/00 ,  C12Q1/6881 ,  C07K14/47 ,  C12N15/115 ,  C12N5/0783 ,  G01N33/569 ,  C07K14/705

CPC classification number: C07K14/70539 ,  C07K16/303 ,  C07K16/2833 ,  C12P21/02 ,  A61K51/1027 ,  A61K51/1057 ,  A61K39/0011 ,  C12Q1/6881 ,  C07K14/4748 ,  C12N15/115 ,  C12N5/0636 ,  G01N33/56977 ,  C07K14/70503 ,  A61K2039/5158 ,  G01N2333/70539 ,  C12Q2600/156 ,  C12N2310/16 ,  C12Q2600/158 ,  C07K2319/55 ,  C07K2319/30 ,  C07K2319/00 ,  C07K2317/72 ,  C07K2317/73 ,  A61K2039/572

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230190807A1

公开(公告)日：2023-06-22

申请号：US17938317

申请日：2022-10-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Frank SCHWOEBEL ,  Lena Katharina FREUDENMANN

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/04 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/04 ,  C07K16/2809 ,  C07K2317/55 ,  C07K2317/626 ,  C07K2317/73

Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).

公开(公告)号：US20230181729A1

公开(公告)日：2023-06-15

申请号：US17938505

申请日：2022-10-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Frank SCHWOEBEL ,  Lena Katharina FREUDENMANN

IPC: A61K39/385 ,  A61P35/04

CPC classification number: A61K39/385 ,  A61P35/04 ,  A61K2039/53

Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).